Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 safety and efficacy study of Aldurazyme (laronidase) in Chinese participants with Mucopolysaccharidosis I
2023-001027-16Phase 4
- Sponsor
- Sanofi
- Start
- Nov 2023
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of laronidase in mucopolysaccharidosis type I, sponsored by Sanofi. Primary endpoint: Participants with adverse events.
02
Drugs
laronidase
03
Conditions
mucopolysaccharidosis type I
Beyond the preview
Go deeper on 2023-001027-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-001027-16.